Default Category
-
Merck Sharp & Dohme Argentina, Inc. (A)
Paine, Lynn Sharp; Hogan, Harold F., Jr.Case HBS-398033-EKnowledge and CommunicationDescribes the efforts of the new managing director of Merck's subsidiary for Argentina, Uruguay, and Paraguay to transform the organization and its culture. Focuses on a critical decision: whether to offer the son of a high-ranking official in the governmStarting at €8.20
-
BioRecilGent (B)
Miguel A. Ariño; Rodríguez Mariscal, ManuelCase AD-381-EDecision AnalysisThe case focuses on the development of a yet-to-be-approved drug. It presents the various options open to the company developing the drug in the context of the phases that the medicine must go through to be approved.Starting at €5.74
-
BioRecilGent (A)
Miguel A. Ariño; Rodríguez Mariscal, ManuelCase AD-380Decision AnalysisEl caso presenta el desarrollo de un fármaco que todavía no está aprobado. Muestra las distintas opciones que tiene la empresa que lo desarrolla, según las diferentes fases para su aprobación.Starting at €8.20
-
Merck Sharp & Dohme Argentina, Inc. (A) (Spanish version)
Paine, Lynn Sharp; Hogan, Harold F., Jr.Case HBS-303S38Strategywhether to offer the son of a high-ranking official in the government's national health-care program a place in the company's highly selective intern program for young professionals.Starting at €8.20
-
BioRecilGent (B)
Miguel A. Ariño; Rodríguez Mariscal, ManuelCase AD-381Decision AnalysisEl caso presenta el desarrollo de un fármaco que todavía no está aprobado. Muestra las distintas opciones que tiene la empresa que lo desarrolla, según las diferentes fases para su aprobación.Starting at €5.74
-
BioRecilGent (A)
Miguel A. Ariño; Rodríguez Mariscal, ManuelCase AD-380-EDecision AnalysisThe case focuses on the development of a yet-to-be-approved drug. It presents the various options open to the company developing the drug in the context of the phases that the medicine must go through to be approved.Starting at €8.20